Scrip Asks... What Will 2019 Hold For Biopharma? Part 1: Therapeutic Advances
Executive Summary
Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.
You may also be interested in...
Exelixis’s Cabometyx Plus Tecentriq Disappoints In Lung Cancer
While a combo regimen of Cabometyx and Tecentriq actually showed a lower response rate in lung cancer than a 2020 readout, a doublet of Cabometyx/Keytruda showed promise in head-and-neck cancer.
PBM Formulary Exclusions On The Rise, PhRMA Says
According to a report commissioned by PhRMA, the three largest pharmacy benefit managers continue to exclude more drugs from standard formularies, including those with expedited FDA approval.
Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.